UK Markets closed

Bone Biologics Corporation (BBLG)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9900-0.1000 (-4.78%)
At close: 04:00PM EDT
1.9616 -0.03 (-1.43%)
After hours: 07:45PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.30M
Enterprise value -927.61k
Trailing P/E 0.11
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.63
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.13

Trading information

Stock price history

Beta (5Y monthly) 0.67
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 311.7600
52-week low 31.0000
50-day moving average 31.4500
200-day moving average 32.8138

Share statistics

Avg vol (3-month) 3940.14k
Avg vol (10-day) 35.23M
Shares outstanding 51.1M
Implied shares outstanding 6N/A
Float 81.01M
% held by insiders 16.51%
% held by institutions 14.74%
Shares short (15 Jul 2024) 45.32k
Short ratio (15 Jul 2024) 40.05
Short % of float (15 Jul 2024) 40.50%
Short % of shares outstanding (15 Jul 2024) 40.48%
Shares short (prior month 14 Jun 2024) 421.75k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 324 Jul 2018
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 313 Oct 2021

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-84.54%
Return on equity (ttm)-189.37%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-6.1M
Diluted EPS (ttm)19.8800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.23M
Total cash per share (mrq)2.93
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)23.32
Book value per share (mrq)3.62

Cash flow statement

Operating cash flow (ttm)-9.51M
Levered free cash flow (ttm)-8.19M